You searched for "nAMD"
Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...inserts
Eye News April/May 2022Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service
3 April 2023
| Yasir Khan, Robin Hamilton, Adam Mapani, Catey Bunce, Ranjan Rajendram, Carlos Pavesio
|
Ophthalmology
Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...
Celebrating eight years of the nurse-led intravitreal injection service
4 February 2021
| Adam Mapani, Robin Hamilton, Jonah Nago, Gavin Kissoondeeal, Bhavin Maru, Musa Sanyang, Rankin Pacheco, Helen Carpenter, Julie Sharma, Mary Masih, Tracy Luckett, Kate Falkner
|
Ophthalmology, Retina / Uvea / Vitreous
Moorfields Eye Hospital NHS Foundation Trust in London celebrated the eighth year of its nurse-led intravitreal (IVT) injection service in 2020. In collaboration with Beaver-Visitec International (BVI), Moorfields’ comprehensive one-day course for non-medical staff has blossomed into a thriving success....
Age-related macular degeneration
1 December 2015
| Nana Theodorou
|
Retina / Uvea / Vitreous
This review article offers an up to date review of the genetic and environmental risk factors associated with aetiology surrounding age-related macular degeneration (AMD). The article briefly describes the typical clinical presentation relating to early and late stages of the...
Four year outcomes of macular degeneration treated with ranibizumab
1 February 2014
| Brian Ang
|
Retina / Uvea / Vitreous
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
Features of AMD treatment non-responders
This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...Characteristics of Charles Bonnet syndrome in patients with neovascular AMD
7 April 2021
| Ed Rule
|
Retina / Uvea / Vitreous
|
Age-related macular degeneration, Charles Bonnet syndrome, Low vision, Negative outcome, Visual hallucinations
This retrospective cross-sectional study aimed to characterise various aspects of Charles Bonnet syndrome hallucinations among patients with neovascular age-related macular degeneration (AMD). Five hundred and ten consecutive patients were asked a screening question to determine if they had ever suffered...
Changes in drusen and retinal layer volumes prior to CNV development
7 April 2021
| Ed Rule
|
Retina / Uvea / Vitreous
|
Age-related macular degeneration, Choroidal neovascularisation type, Drusen load, Imaging biomarkers, Retinal layer volumes
This retrospective longitudinal study looked at patients with wet age-related macular degeneration (AMD) in one eye who subsequently developed wet AMD in the fellow eye. The aim was to discover whether drusen characteristics or volumes of retinal layers correlate with...
In conversation with Professor Usha Chakravarthy (2018)
Professor Chakravarthy popped by the Eye News stand at the 2018 Royal College of Ophthalmologists Annual Congress after her excellent Bowman Lecture. She gave us a summary of her presentation, which looked at how our understanding of AMD has changed...New partnership to prevent unnecessary sight loss
13 December 2022
Sight loss charity the Macular Society has announced a new partnership with OcuPlan, a service designed to give patients with long-term eye conditions such as macular disease affordable access to specialist care to prevent unnecessary sight loss.